TNF-α

Genetic Background:

C57BL/6 Background

Origin:

The TNF-α mouse was developed by Xenogen Biosciences, now Taconic. The model was created by microinjecting the human TNF-α gene. Taconic received stock in April 1996 at the second backcross from the C57BL/6 x SJL founder line. The mice were maintained by backcrossing hemizygous TNF-α mice to C57BL/6NTac inbred mice.

Color:

Black

Species:

Mouse

Initial Publication:

ayward MD, Jones BK, Saparov A, Hain HS, Trillat A-C, Bunzel MM, Corona A, Li-Wang B, Strenkowski B, Giordano C, Shen H, Arcamone E, Weidlick J, Vilensky M, Tugusheva M, Felkner RH, Campbell W, Rao Y, Grass DS, Buiakova O. (2007) An extensive phenotypic characterization of the hTNFα transgenic mice. BMC Physiology, 7:13.

Animal Diet:

NIH #31M Rodent Diet

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:

• Title to these Models and biological materials derived from them remains with Taconic.
• The Models will be used for research purposes only.
• The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
• The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
• Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.

View the production locations(s) and the accompanying current IHMS™ Health Report and Taconic Health Standard for this model

Phenotypic Clinical Chemistries of TNF-α

Total and Differential Cell Counts for TNF-α using FACS Analysis

Pathology Report

Phenotypic Disease Observations:

Onset of Arthritis-Clinical Signs in Hindlimbs
TNF-α Transgenic Mice and non-transgenic age-matched controls comparing signs of disease progression.

5 weeks: normal appearance; no detectable symptoms

9 weeks: mild disease; minor loss of flexibility in digits; minimal joint swelling and distortion

14 weeks: moderate disease; moderate distortion and twisting of hindpaw and moderate swelling of joints

20 weeks: severe disease; distortion and swelling of joints